These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19669408)

  • 1. Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma.
    Kamal M; Shaaban AM; Zhang L; Walker C; Gray S; Thakker N; Toomes C; Speirs V; Bell SM
    Breast Cancer Res Treat; 2010 Jun; 121(3):555-63. PubMed ID: 19669408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
    van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
    Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
    J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.
    Heinonen M; Bono P; Narko K; Chang SH; Lundin J; Joensuu H; Furneaux H; Hla T; Haglund C; Ristimäki A
    Cancer Res; 2005 Mar; 65(6):2157-61. PubMed ID: 15781626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
    Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
    Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
    Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
    J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
    Cho MH; Yoon JH; Jaegal YJ; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Lee MC; Park CS; Woo Juhng S; Min KW
    Breast; 2006 Jun; 15(3):390-8. PubMed ID: 16169726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
    Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
    J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of Cripto and its prognostic significance in breast cancer: a study with long-term survival.
    Gong YP; Yarrow PM; Carmalt HL; Kwun SY; Kennedy CW; Lin BP; Xing PX; Gillett DJ
    Eur J Surg Oncol; 2007 May; 33(4):438-43. PubMed ID: 17125961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival analysis between patients with invasive ductal and invasive lobular breast cancer.
    Dian D; Herold H; Mylonas I; Scholz C; Janni W; Sommer H; Friese K
    Arch Gynecol Obstet; 2009 Jan; 279(1):23-8. PubMed ID: 18449551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
    Oliveira VM; Piato S; Silva MA
    Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma.
    Pula B; Jethon A; Piotrowska A; Gomulkiewicz A; Owczarek T; Calik J; Wojnar A; Witkiewicz W; Rys J; Ugorski M; Dziegiel P; Podhorska-Okolow M
    Histopathology; 2011 Dec; 59(6):1249-60. PubMed ID: 22175904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
    Rakha EA; Abd El Rehim D; Pinder SE; Lewis SA; Ellis IO
    Histopathology; 2005 Jun; 46(6):685-93. PubMed ID: 15910600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer.
    Yamamoto Y; Ibusuki M; Okumura Y; Kawasoe T; Kai K; Iyama K; Iwase H
    Breast Cancer Res Treat; 2008 Aug; 110(3):465-75. PubMed ID: 17805961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
    Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
    Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.